Clinical Trial

A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS-4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-18.
Status change: Not Yet Recruiting → Recruiting 2026-06-25
Trial Details
NCT Number NCT07140393
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Solid Tumor
Enrollment 120 participants
Start Date 2025-10-28
Primary Completion 2027-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-29